Azithromycin and the Risk of Cardiovascular Death

Overview

Journal N Engl J Med

Specialty General Medicine

Date 2012 May 18

PMID 22591294

Citations 349

Authors

Wayne A Ray

Katherine T Murray

Kathi Hall

Patrick G Arbogast

C Michael Stein

Affiliations

Soon will be listed here.

Abstract

Background: Although several macrolide antibiotics are proarrhythmic and associated with an increased risk of sudden cardiac death, azithromycin is thought to have minimal cardiotoxicity. However, published reports of arrhythmias suggest that azithromycin may increase the risk of cardiovascular death.

Methods: We studied a Tennessee Medicaid cohort designed to detect an increased risk of death related to short-term cardiac effects of medication, excluding patients with serious noncardiovascular illness and person-time during and shortly after hospitalization. The cohort included patients who took azithromycin (347,795 prescriptions), propensity-score-matched persons who took no antibiotics (1,391,180 control periods), and patients who took amoxicillin (1,348,672 prescriptions), ciprofloxacin (264,626 prescriptions), or levofloxacin (193,906 prescriptions).

Results: During 5 days of therapy, patients taking azithromycin, as compared with those who took no antibiotics, had an increased risk of cardiovascular death (hazard ratio, 2.88; 95% confidence interval [CI], 1.79 to 4.63; P<0.001) and death from any cause (hazard ratio, 1.85; 95% CI, 1.25 to 2.75; P=0.002). Patients who took amoxicillin had no increase in the risk of death during this period. Relative to amoxicillin, azithromycin was associated with an increased risk of cardiovascular death (hazard ratio, 2.49; 95% CI, 1.38 to 4.50; P=0.002) and death from any cause (hazard ratio, 2.02; 95% CI, 1.24 to 3.30; P=0.005), with an estimated 47 additional cardiovascular deaths per 1 million courses; patients in the highest decile of risk for cardiovascular disease had an estimated 245 additional cardiovascular deaths per 1 million courses. The risk of cardiovascular death was significantly greater with azithromycin than with ciprofloxacin but did not differ significantly from that with levofloxacin.

Conclusions: During 5 days of azithromycin therapy, there was a small absolute increase in cardiovascular deaths, which was most pronounced among patients with a high baseline risk of cardiovascular disease. (Funded by the National Heart, Lung, and Blood Institute and the Agency for Healthcare Quality and Research Centers for Education and Research on Therapeutics.).

Citing Articles

Cardiovascular Toxicity Profile of Macrolides Investigated Using VigiBase Data: A Pharmacovigilance Study.

Kono Y, Niimura T, Goda M, Ueta S, Kawada K, Miyata K Cardiovasc Toxicol. 2025; 25(3):498-506.

PMID: 39971867 PMC: 11885371. DOI: 10.1007/s12012-025-09970-w.

Pulmonary Delivery of Antibiotics to the Lungs: Current State and Future Prospects.

Dallal Bashi Y, Mairs R, Murtadha R, Kett V Pharmaceutics. 2025; 17(1).

PMID: 39861758 PMC: 11768398. DOI: 10.3390/pharmaceutics17010111.

The role of empiric atypical antibiotic coverage in non-severe community-acquired pneumonia.

Hartlage W, Imlay H, Spivak E Antimicrob Steward Healthc Epidemiol. 2025; 4(1):e214.

PMID: 39758879 PMC: 11696604. DOI: 10.1017/ash.2024.453.

Assessment of azithromycin-induced toxicity in : Effects on morphology, behavior, and lipid metabolism.

Kalugendo E, Nazir A, Agarwal R Toxicol Rep. 2024; 13:101832.

PMID: 39717856 PMC: 11664063. DOI: 10.1016/j.toxrep.2024.101832.

Emerging Anti-Inflammatory COPD Treatments: Potential Cardiovascular Impacts.

Cazzola M, Calzetta L, Rogliani P, Matera M Int J Chron Obstruct Pulmon Dis. 2024; 19:2481-2495.

PMID: 39606712 PMC: 11600434. DOI: 10.2147/COPD.S498255.

References

Landry J, Smyer M, Tubman J, Lago D, Roberts J, Simonson W . Validation of two methods of data collection of self-reported medicine use among the elderly. Gerontologist. 1988; 28(5):672-6. DOI: 10.1093/geront/28.5.672. View

Sturmer T, Schneeweiss S, Brookhart M, Rothman K, Avorn J, Glynn R . Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol. 2005; 161(9):891-8. PMC: 1407370. DOI: 10.1093/aje/kwi106. View

De Ponti F, Poluzzi E, Montanaro N . QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol. 2000; 56(1):1-18. DOI: 10.1007/s002280050714. View

Poluzzi E, Raschi E, Moretti U, De Ponti F . Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf. 2009; 18(6):512-8. DOI: 10.1002/pds.1746. View

Matsunaga N, Oki Y, Prigollini A . A case of QT-interval prolongation precipitated by azithromycin. N Z Med J. 2003; 116(1185):U666. View

Kezerashvili A, Khattak H, Barsky A, Nazari R, Fisher J . Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors. J Interv Card Electrophysiol. 2007; 18(3):243-6. DOI: 10.1007/s10840-007-9124-y. View

Straus S, Sturkenboom M, Bleumink G, Dieleman J, van der Lei J, de Graeff P . Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J. 2005; 26(19):2007-12. DOI: 10.1093/eurheartj/ehi312. View

Arbogast P, Kaltenbach L, Ding H, Ray W . Adjustment for multiple cardiovascular risk factors using a summary risk score. Epidemiology. 2007; 19(1):30-7. DOI: 10.1097/EDE.0b013e31815be000. View

Ray W, Griffin M . Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol. 1989; 129(4):837-49. DOI: 10.1093/oxfordjournals.aje.a115198. View

10.

West S, Savitz D, Koch G, Strom B, Guess H, Hartzema A . Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol. 1995; 142(10):1103-12. DOI: 10.1093/oxfordjournals.aje.a117563. View

11.

Ray W, Murray K, Meredith S, Narasimhulu S, Hall K, Stein C . Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004; 351(11):1089-96. DOI: 10.1056/NEJMoa040582. View

12.

Ray W . Population-based studies of adverse drug effects. N Engl J Med. 2003; 349(17):1592-4. DOI: 10.1056/NEJMp038145. View

13.

Koh T . Risk of torsades de pointes from oral erythromycin with concomitant carbimazole (methimazole) administration. Pacing Clin Electrophysiol. 2001; 24(10):1575-6. DOI: 10.1046/j.1460-9592.2001.01575.x. View

14.

Kannankeril P, Roden D, Darbar D . Drug-induced long QT syndrome. Pharmacol Rev. 2010; 62(4):760-81. PMC: 2993258. DOI: 10.1124/pr.110.003723. View

15.

Arellano-Rodrigo E, Garcia A, Mont L, Roque M . [Torsade de pointes and cardiorespiratory arrest induced by azithromycin in a patient with congenital long QT syndrome]. Med Clin (Barc). 2001; 117(3):118-9. DOI: 10.1016/s0025-7753(01)72036-2. View

16.

Owens Jr R, Nolin T . Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis. 2006; 43(12):1603-11. DOI: 10.1086/508873. View

17.

Vogt A, Zollo R . Long Q-T syndrome associated with oral erythromycin used in preoperative bowel preparation. Anesth Analg. 1997; 85(5):1011-3. DOI: 10.1097/00000539-199711000-00010. View

18.

Russo V, Puzio G, Siniscalchi N . Azithromycin-induced QT prolongation in elderly patient. Acta Biomed. 2006; 77(1):30-2. View

19.

Johnson R, Vollmer W . Comparing sources of drug data about the elderly. J Am Geriatr Soc. 1991; 39(11):1079-84. DOI: 10.1111/j.1532-5415.1991.tb02872.x. View

20.

Samarendra P, Kumari S, Evans S, Sacchi T, Navarro V . QT prolongation associated with azithromycin/amiodarone combination. Pacing Clin Electrophysiol. 2001; 24(10):1572-4. DOI: 10.1046/j.1460-9592.2001.01572.x. View